|
Targacept says drug candidate worked as an asthma treatment, but fails as …
Greenfield Daily Reporter AP WINSTON-SALEM, NC — Shares of Targacept Inc. declined Tuesday after the company said its drug candidate TC-6987 worked as a treatment for asthma in a clinical trial, but failed as a treatment for diabetes. Targacept said asthma patients who were … Targacept Announces Top-Line Results from Two Exploratory Phase 2 Studies of … Asthma drug shows promise, diabetes study fails in Targacept phase 2 trials Targacept reports mixed data from two trials |
View full post on asthma – Google News